3F8

CAS No. 159109-11-2

3F8( —— )

Catalog No. M33790 CAS No. 159109-11-2

3F8 is a selective GSK-3β inhibitor that can be used as a new tool and potential therapeutic candidate compound for GSK3-related diseases, and can be used in the study of neurological disorders and cancer.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 162 In Stock
10MG 261 In Stock
25MG 421 In Stock
50MG 551 In Stock
100MG 786 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    3F8
  • Note
    Research use only, not for human use.
  • Brief Description
    3F8 is a selective GSK-3β inhibitor that can be used as a new tool and potential therapeutic candidate compound for GSK3-related diseases, and can be used in the study of neurological disorders and cancer.
  • Description
    3F8 is a potent and selective GSK-3β inhibitor that could be useful as new reagent and potential therapeutic candidate for GSK3 related diseases.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    PI3K/Akt/mTOR signaling
  • Target
    GSK-3
  • Recptor
    GSK-3
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    159109-11-2
  • Formula Weight
    286.28
  • Molecular Formula
    C15H14N2O4
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CCC1=NC2=C(C(=O)NC2=O)C2=C1C=C(OC)C(OC)=C2
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Zhong H, et al. Characterization and development of novel small-molecules inhibiting GSK3 and activating Wnt signaling. Mol Biosyst. 2009 Nov;5(11):1356-60.?
molnova catalog
related products
  • 4-Chloro-2-bromoacet...

    4-Chloro-2'-bromoacetophenone against glycogen synthase kinase-3 (GSK-3beta).

  • WAY-352753

    WAY-352753 is a GSK3B-glycogen synthase kinase-3 beta inhibitor.

  • TDZD-8

    A potent, selective, non-ATP competitive GSK-3β inhibitor with IC50 of 2 uM; displays no activity against PKA, CK-2, PKC, and CDK1 (IC50>100 uM).